



Find the an Apptonton Garner Specialist

Madert 2018 Autie Otentoreen & Treatment

Refer a Patient

ABOUT US

Our mission, vision & core values

Leadership

History

Equality, diversity & inclusion

Annual report

Give to MSK

Bladder Cancer

Upper Tract

Urologic Oncology

View all ¥





Languages: English

Request an Appointment

Our Care Advisors can answer many of your questions. They will connect you with the best healthcare provider for your needs.

•

Call 646-497-9068

Make an appointment

Guido Dalbagni 1/9

About Me

What I Do at MSK

Attending Surgeon

Get To Know Me

I am a urologic surgeon with expertise in the treatment of urologic tumors — which include bladder, urethral, and kidney cancers.

I am currently heading clinical trials at Memorial Sloan Kettering Cancer Center to evaluate new therapies for the treatment of high-risk superficial bladder cancer in patients who are resistant to bacillus Calmette-Guérin (BCG) therapy, the standard treatment. I also have expertise in nerve-sparing radical cystectomy followed by bladder reconstruction.

This provider is part of a team that was ranked #1 in the nation for Urology Cancer Care this year by *U.S. News & World Report*.

Read more

i

My Role at MSK

A urologic surgeon is a doctor with special training in surgery on the genitourinary (jeh-nih-toh-YOOR-ih-nayr-ee) (GU) system. This includes the bladder, kidney, penis, prostate, and testicles.

Areas of Expertise

My Specialties

Bladder Cancer

Upper Tract

Urologic Oncology

Kidney Cancer

Education & Honors

Education

MBBCh, Cairo University Faculty of Medicine

Guido Dalbagni 2/9

Residencies

General Surgery - Cabrini Medical Center
Urology - New York University Medical Center

Fellowships

Urologic Oncology - Memorial Sloan Kettering Cancer Center

Board Certifications

Urology

Insurance Information

Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.

Enter your insurance provider

Don't see your carrier or plan? We can help you understand your coverage.

If you don't have health insurance or are worried that your care may not be fully covered, our <u>financial assistance</u> programs may be able to help.

If you have questions about insurance, call us at 646-497-9176.

Make an Appointment

Guido Dalbagni 3/9



New Patients

Scheduling an appointment is easy. Click or call 646-497-9068— we're available Monday through Friday, 8 a.m. to 6 p.m. (Eastern time)

Make an Appointment

Current Patients

Guido Dalbagni 4/9

Request an appointment by logging on to MyMSK or calling your doctor's office. If you aren't registered for MyMSK, call 646-227-2593 for your Enrollment ID.

Contact and Location

Dr. Dalbagni sees patients at two locations.

Office Phone

646-422-4394

Location





Sidney Kimmel Center for Prostate and Urologic Cancers

353 East 68th Street New York, NY 10065 Get Directions

Memorial Sloan Kettering Bergen



Looking to see a doctor at a different location? See all MSK locations.

Colleagues

Guido Dalbagni 5/9

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

See all Urology Service doctors



Clinical Trials

Clinical Trials Co-Investigated by Dr. Dalbagni

A Phase I/II Study Assessing the Addition of Gemcitabine to BCG Treatment in People with High-Grade Non-Muscle Invasive Bladder Cancer that Returned after Prior BCG



Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Search clinical trials



Research and Publications

Dalbagni G, Russo P, Sheinfeld J, Mazumdar M, Tong W, Rabbani F, Donat MS, Herr HW, Sogani P, dePalma D, Bajorin D. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder.. J Clin Oncol. 2002; 20(15):3193-8

<u>Dalbagni G, Herr HW, Reuter VE. Impact of a second transurethral resection on the staging of T1 bladder cancer.. Urology 2002;</u> 60(5):824-825

<u>Dalbagni G, Donat SM, Eschwege P, Herr HW, Zelefsky MJ. Results of high-dose brachytherapy (HDR-BRT), anterior pelvic exenteration and external beam radiotherapy for carcinoma of the female urethra. J Urol 2001; 166:1759-1761</u>

<u>Dalbagni G, Ren Z-P, Herr HW, Cordon-Cardo C, Reuter VE. Genetic alterations in TP53 in recurrent urothelial cancer: A longitudinal study. CI Cancer Res 2001; 7:1797-2801</u>

<u>Dalbagni G, Genega E, Hashibe M, Zhang Z-F, Russo P, Herr HW, Reuter V. Cystectomy for Bladder Cancer: A Contemporary Series. J Urol 2001; 165 :1111-1116</u>

Cozzi PJ, Bajorin DF, Tong W, Nguyen H, Scott J, Heston WDW, Dalbagni G. Toxicology and Pharmacokinetics of Intravesical

Guido Dalbagni 6/9

Gemcitabine: A Preclinical Study in Dogs. CI Cancer Res 1999; 5:2629-2637

<u>Dalbagni G, Reschtschaffen T, Herr HW. Is Transurethral Biopsy of the Bladder Necessary After 3 Months to Evaluate Response to BCG Therapy. J Urol 1999; 162</u>:708-709

<u>Dalbagni G, Zhang Z-F, Lacombe L, Herr HW. Male Urethral Carcinoma: Analysis of Treatment Outcome. Urology 1999; 53:1126-1132</u>

<u>Dalbagni G, Zhang Z-F, Lacombe L, Herr HW. Female Urethral Carcinoma: Analysis of treatment outcome and a plea for a standardized management strategy. Br J Urol 1998; 82 :835-841</u>

Publications on PubMed

Visit PubMed for a full listing of Dr. Dalbagni's journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

See all on PubMed



Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report ("disclose") the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Guido Dalbagni discloses the following relationships and financial interests:

No disclosures meeting criteria for time period


If you're a patient at MSK and would like more information about your doctor's external relationships, please talk with your doctor.

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK's COI policies <u>here</u>. For questions regarding MSK's COI-related policies and procedures, email MSK's Compliance Office at <u>ecoi@mskcc.org</u>.

Guido Dalbagni 7/9



Guido Dalbagni

Price transparency

Public notices

© 2024 Memorial Sloan Kettering Cancer Center

Guido Dalbagni 9/9